Tempest Therapeutics (TPST) Competitors $8.88 -0.07 (-0.78%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$8.89 +0.01 (+0.11%) As of 04:35 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TPST vs. ADAG, ORMP, OPTN, HLVX, CCCC, ANIX, COYA, MIST, GNLX, and ZNTLShould you be buying Tempest Therapeutics stock or one of its competitors? The main competitors of Tempest Therapeutics include Adagene (ADAG), Oramed Pharmaceuticals (ORMP), OptiNose (OPTN), HilleVax (HLVX), C4 Therapeutics (CCCC), Anixa Biosciences (ANIX), Coya Therapeutics (COYA), Milestone Pharmaceuticals (MIST), Genelux (GNLX), and Zentalis Pharmaceuticals (ZNTL). These companies are all part of the "pharmaceutical products" industry. Tempest Therapeutics vs. Adagene Oramed Pharmaceuticals OptiNose HilleVax C4 Therapeutics Anixa Biosciences Coya Therapeutics Milestone Pharmaceuticals Genelux Zentalis Pharmaceuticals Tempest Therapeutics (NASDAQ:TPST) and Adagene (NASDAQ:ADAG) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment, community ranking and earnings. Does the MarketBeat Community believe in TPST or ADAG? Tempest Therapeutics received 79 more outperform votes than Adagene when rated by MarketBeat users. However, 79.31% of users gave Adagene an outperform vote while only 64.56% of users gave Tempest Therapeutics an outperform vote. CompanyUnderperformOutperformTempest TherapeuticsOutperform Votes10264.56% Underperform Votes5635.44% AdageneOutperform Votes2379.31% Underperform Votes620.69% Do analysts recommend TPST or ADAG? Tempest Therapeutics currently has a consensus target price of $30.00, suggesting a potential upside of 237.84%. Adagene has a consensus target price of $8.00, suggesting a potential upside of 308.16%. Given Adagene's higher probable upside, analysts plainly believe Adagene is more favorable than Tempest Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tempest Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50Adagene 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do insiders & institutionals believe in TPST or ADAG? 22.5% of Tempest Therapeutics shares are owned by institutional investors. Comparatively, 9.5% of Adagene shares are owned by institutional investors. 4.7% of Tempest Therapeutics shares are owned by company insiders. Comparatively, 21.2% of Adagene shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more volatility & risk, TPST or ADAG? Tempest Therapeutics has a beta of -2, indicating that its share price is 300% less volatile than the S&P 500. Comparatively, Adagene has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500. Does the media favor TPST or ADAG? In the previous week, Tempest Therapeutics had 5 more articles in the media than Adagene. MarketBeat recorded 6 mentions for Tempest Therapeutics and 1 mentions for Adagene. Adagene's average media sentiment score of 1.87 beat Tempest Therapeutics' score of 0.29 indicating that Adagene is being referred to more favorably in the news media. Company Overall Sentiment Tempest Therapeutics Neutral Adagene Very Positive Which has preferable valuation and earnings, TPST or ADAG? Adagene has higher revenue and earnings than Tempest Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTempest TherapeuticsN/AN/A-$29.49M-$17.98-0.49Adagene$103.20K894.69-$18.95MN/AN/A Is TPST or ADAG more profitable? Adagene's return on equity of 0.00% beat Tempest Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Tempest TherapeuticsN/A -187.44% -82.61% Adagene N/A N/A N/A SummaryAdagene beats Tempest Therapeutics on 9 of the 13 factors compared between the two stocks. Get Tempest Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TPST and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TPST vs. The Competition Export to ExcelMetricTempest TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$32.70M$6.83B$5.57B$8.67BDividend YieldN/A2.50%5.27%4.19%P/E Ratio-5.808.7927.2120.17Price / SalesN/A263.51414.99161.94Price / CashN/A65.8538.2534.64Price / Book6.396.677.124.72Net Income-$29.49M$143.49M$3.23B$247.80M7 Day Performance28.88%5.15%3.80%2.76%1 Month Performance36.83%15.43%13.40%9.71%1 Year Performance-78.04%6.02%32.04%14.51% Tempest Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TPSTTempest Therapeutics1.8898 of 5 stars$8.88-0.8%$30.00+237.8%-78.5%$32.70MN/A-5.8020ADAGAdagene1.4481 of 5 stars$2.09+7.5%$8.00+283.7%-31.2%$98.22M$103,204.000.00260Positive NewsGap DownORMPOramed Pharmaceuticals2.1464 of 5 stars$2.38+1.7%N/A+4.7%$97.22M$2M21.6410Positive NewsOPTNOptiNose1.7894 of 5 stars$9.60flat$9.00-6.3%N/A$97.22M$81.86M-2.29190HLVXHilleVax2.682 of 5 stars$1.93+3.2%$3.00+55.4%-86.1%$96.77MN/A-0.6220Positive NewsCCCCC4 Therapeutics2.1622 of 5 stars$1.33+6.4%$12.00+802.3%-67.4%$94.44M$39.78M-0.78150Positive NewsANIXAnixa Biosciences2.6295 of 5 stars$2.89+12.5%$9.00+211.4%+30.7%$93.05M$210,000.00-7.415Analyst ForecastGap UpHigh Trading VolumeCOYACoya Therapeutics1.8765 of 5 stars$5.55+4.1%$17.00+206.3%-20.7%$92.82M$3.69M-8.546Analyst ForecastGap UpMISTMilestone Pharmaceuticals2.7799 of 5 stars$1.73+6.8%$17.00+882.7%+19.9%$92.49M$1M-2.1430Positive NewsGap UpGNLXGenelux1.1829 of 5 stars$2.45+1.2%$17.75+624.5%+11.7%$92.45M$8,000.00-2.5810Gap UpZNTLZentalis Pharmaceuticals1.727 of 5 stars$1.28+5.8%$8.24+544.1%-84.4%$92.10M$26.87M-0.51160Positive News Related Companies and Tools Related Companies ADAG Alternatives ORMP Alternatives OPTN Alternatives HLVX Alternatives CCCC Alternatives ANIX Alternatives COYA Alternatives MIST Alternatives GNLX Alternatives ZNTL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TPST) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tempest Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tempest Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TPST Stock Free TPST Stock Alerts